The European Patent Office (EPO) has granted patent EP3580338B1, which details methods for cell-type specific profiling to identify markers for nuclei isolation. The patent, designated with the Kind B1, was officially granted on March 18, 2026, and lists Nathaniel Heintz and Xiao Xu as inventors. The International Patent Classification (IPC) codes associated with this patent include C12N 15/11, C12Q 1/68, C12N 5/0793, C12Q 1/6806, and C12Q 1/6841.

This patent grant establishes intellectual property rights related to specific biotechnological methods. While not a regulatory rule imposing obligations on companies, it signifies a new patented technology in the field of cell biology and molecular diagnostics. Companies operating in the biotech and pharmaceutical sectors, particularly those involved in research and development of cell isolation techniques or diagnostic markers, should be aware of this patent to ensure they do not infringe upon the granted claims. The patent is valid in multiple European designated states, including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR.